New Gonorrhea Vaccine Gets Fast-Track Review By FDA
There is hope for STD patients as a new gonorrhea vaccine has been approved for fast-track review by the Food and Drug Administration (FDA). The experimental Neisseria gonorrhoeae investigational vaccine (NgG), developed by British pharmaceutical company GSK plc, will be the first of its kind as the sexually transmitted disease (STD) has never had any preventive measures against it. “We welcome the FDA’s decision to grant Fast Track designation for our new vaccine candidate against Neisseria gonorrhoeae infection,” said Phil Dormitzer, who is the Global Head of Vaccines R&D at GSK. “With a hi...